Zusammenfassung
Das Mammakarzinom ist ein Malignom, das fast ausschließlich durch Fernmetastasierung und nicht durch lokales Tumorwachstum zum Tode führt. Rund 60% aller Patientinnen mit Mammakarzinom entwickeln innerhalb von zehn Jahren nach der primären Therapie Metastasen (Seidman, 1969). Langfristig können nur etwa 25% aller Patientinnen mit Mammakarzinom definitiv geheilt werden (Welbourn U. Burn, 1972). Das Risiko, nach erfolgreicher Radikaloperation eines Mammakarzinoms infolge Fernmetastasierung zu sterben, besteht auch noch nach einer Beobachtungsdauer von mehr als 20 Jahren (Ederer etal, 1963; Whitney et al, 1964). Rund 75% aller Patientinnen mit diesem Karzinom benötigen daher zu irgendeinem Zeitpunkt eine palliative Behandlung in einem nicht heilbaren Stadium. Der klinische Verlauf des Mammakarzinoms ist sehr unterschiedlich. Einige Karzinome führen rasch zum Tode, unabhängig davon, welche kurativen oder palliativen Therapien eingeleitet werden. Andere zeigen sehr langsame Verläufe. Dazwischen liegen zahlreiche Krankheitsverläufe, die heute in zunehmendem Maße auch im metastasierenden Stadium objektiv und subjektiv günstig beeinflußt werden können. Die großen Unterschiede im Spontanverlauf des Mammakarzinoms machen es schwierig, ohne exakt definierte Kriterien die Wirksamkeit irgendeiner Behandlungsmethode zu bewerten.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ahman, D.L., Eagan, R.T., Bisel, H.F., Hahn, R.G., O’Connell, M.J., Edmondson, J.H.: Evaluation of combination therapy with adriamycin (NSC-123 127) and methotrexate (NSC-740) in patients with disseminated breast cancer. Cancer Chemother. Rep. 6/3, 335–338 (1975a)
Ahman, D.L., Bisel, H.F., Hahn, R.G. et al.: An analysis of a multiple-drug program in the treatment of patients with advanced breast cancer utilizing 5-Fluorouracil, cyclophosphamide, and prednisone with or without vincristine. Cancer 36, 1925–1935 (1975b)
Ahman, D.L., O’Connell, M.J., Hahn, R.G. Bisel, H.F., Lee, R.A., Edmondson, J.H.: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N. Engl. J. Med. 29, 356–360 (1977)
Band, P.R., Tormey, D.C., Bauer, M.: Induction chemotherapy and maintenance chemo-hormontherapy in metastatic breast cancer (abstr.). Proc. Am. Assoc. Cancer Res. 18, 228 (1977)
Baulieu, E.E.: Steroid receptors and hormone receptivity: new approaches in pharmacology and therapeutics. In: Breast cancer, trends in research and treatment. Heuson, J.C., Mattheiem, W.H., Rozencweig, M. (eds.), pp. 165–183. New York: Raven Press 1977
Benjamin, R.S., Wiernik, P.H., Bachur, N.R.: Adriamycinefficacy, safety, and pharmacologic basis of a single dose schedule (abstr.). Cancer Chemother. Rep. 57, 98 (1973)
Blumenschein, G., Cardenas, J., Freireich, E., Gottlieb, J.: FAC chemotherapy for breast cancer (abstr.). Proc. Am. Assoc. Cancer Res. 15, 193 (1974)
Bogden, A.E., Ebber, H.J., Taylor, D.J., Gray, J.H.: Comparative study of surgery, chemotherapy and immunotherapy alone and in combination on metastases of 13762 mammary adenocarcinoma. Cancer Res. 34, 1627–1631 (1974)
Bonadonna, G., Monfardini, S., DeLena, M., Fossati-Bellani, F., Beretta, G.: Clinical trials with adriamycin. Results of a three-year study. In: International symposium on adriamycin. Carter, S.K., Di-Marco, A., Ghione, M., Krakoff, I.H., Mathé, G. (eds.), pp. 139–152. Berlin, Heidelberg, New York: Springer 1972
Bonadonna G., Rossi, A., Valagussa, P., Banfi, A., Veronesi, U.: The C.M.F program for operable breast cancer with positive axillary nodes. Cancer 39, 2904–2915 (1977)
Broder, L.E., Tormey, D.C.: Combination chemotherapy of carcinom of the breast. Cancer Treat. Rev. 1, 183–203 (1974)
Brunner, K.W., Nagel, G.A.: Internistische Krebstherapie. Berlin, Heidelberg, New York: Springer 1976
Brunner, K.W., Sonntag, R.W., Martz, G., Senn, H.J., Obrecht, P., Alberto, P.: A controlled study in the use of combined drug therapy for metastatic breast cancer. Cancer 36, 1208–1219 (1975)
Brunner, K.W., Sonntag, R.W., Alberto, P., Senn, H.J., Martz, G., Obrecht, P.: Combined chemo-and hormonal therapy in advanced breast cancer. Cancer 39, 2923–2933 (1977)
Canellos, G.P., Taylor, S.G., Band, P., Pocock, S.: Combination chemotherapy for advanced breast cancer (abstr.). Proc. XIth Int. Cancer Congr. 3, 596 (1974)
Canellos, P.G., Pocock S.J., Taylor, S.G. et al.: Combination chemotherapy for metastatic breast carcinoma. Cancer 38, 1882–1886 (1976)
Carbone, P.P., Bauer, M., Band, P., Tormey, D.: Chemotherapy of disseminated breast cancer. Cancer 39, 2916–2922 (1977)
Carter, S.K.: Chemotherapy of breast cancer: current status. In: Breast cancer, trends in research and treatment. Heuson, J.C., Mattheiem, W.H., Rozencweig, M. (eds.), pp. 196–215. New York: Raven Press 1976
Cole, M.P.: Suppression of ovarian function in primary breast cancer. In: Prognostic factors in breast cancer. Forrest, A.P.M., Kunkler P.B. (eds.), p. 146. Edinburgh, London: Livingstone 1968
Cooper, R.: Combination chemotherapy in hormone resistant breast cancer (abstr.). Proc. Am. Assoc. Cancer Res. 10, 15 (1969)
Cortes, E.P., Holland, J.F., Wang, J.J., Sinks, L.F., Blom, J., Senn, H.J., Bank, A., Glidewell, O.: Amputation and adriamycin in primary osteosarcoma. N. Engl. J. Med. 291, 998–1002 (1974)
Creech, R., Harris, D., Grotzinger, P., Engstrom, P.: Low dose therapy of metastatic breast cancer with CAMF vs. sequential C.M.F and adriamycin (abstr.). Proc. Am. Soc. Clin. Oncology 18, 300 (1977)
Davis, H.L., Ramirez, G., Ellerby, R.A., Ansfield, F.J.: Five-drug therapy in advanced breast cancer. Factors influencing toxicity and response. Cancer 34, 239–245 (1974)
DeJager, R., Kaufman, R., Ocahoa, M., Krakoff, L.H.: Chemotherapy of advanced breast cancer with a combination of Cytoxan, adriamycin, and 5-FU (CAF) (abstr.). Proc. Am. Assoc. Cancer Res. 16, 273 (1975)
DeLena, M., DePalo, G.M., Bonadonna, G., Beretta, G., Bajetta, E.: Terapia del carcinoma mammario metastatizzato con ciclofosfamide, methotrexate, vincristina e fluorouracile. Tumori 59, 11–24 (1973)
DeLena, M., Brambilla, C., Morabito, A., Bonadonna, G.: Adriamycin plus vincristine compared with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer. Cancer 35, 1108–1115 (1975)
Eagan, R.T., Ahman, D.L., Admondson, J.H., Hahn, G., Bisel, H.F.: Controlled evaluation of the combination of adriamycin (NSC-123 127), vincristine (NSC-67 574) and methotrexate (NSC-740) in patients with disseminated breast cancer. Cancer Chemother. Rep. 6/3, 339–342 (1975)
Ederer, R., Cutler, S.J., Goldenberg, I.S., Eisenberg, H.: Causes of death among long-term survivors from breast cancer in Connecticut. J. Natl. Cancer Inst. 30, 933–947 (1963)
Fernbach, D.J., Martyn, D.T.: Role of dactinomycyn in the improved survival of children with Wilms’ tumor. J. Am. Med. Assoc. 195, 1005–1009 (1966)
Fisher, B., Ravdin, R.G., Ausman, R.K., Slack, N.H. et al.: Surgical adjuvant chemotherapy in cancer of the breast. Results in a decade of cooperative investigation. Ann. Surg. 168, 337–356 (1968)
Fisher, B., Slack, N, Bross, I.D.J., et al.: Cancer of the breast: size of neoplasm and prognosis. Cancer 24, 1071–1080 (1969)
Fisher, B., Slack, N., Katrych, D., Wolmark, N.: Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg. Gynecol. Obstet. 140, 528–534 (1975)
Fisher, B. et al.: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. Cancer 39, 2883–2901 (1977)
Forrest, A.P.M., Kunkler, P.B. (eds.): Prognostic factors in breast cancer. Edinburgh, London: Livingstone 1968
Fracchia, A.A., Farrow, J.H., Miller, T.R., Rollefsen, R.H., Greenberg, E.J., Knapper, W.H.: Hypophysectomy as compared with adrenalectomy in the treatment of advanced carcinoma of the breast. Surg. Gynecol. Obstet. 133, 241–246 (1971)
Greenspan, E.: Response of advanced breast cancer to the combination of the antimetabolite, methotrexate, and the alkylating agent thio-tepa. Mt. Sinai J. Med. N.Y. 30, 246–267 (1963)
Greenspan, E.: Combination cytotoxic chemotherapy in advanced disseminated breast cancer. Mt. Sinai J. Med. N.Y. 33, 1–27 (1966)
Grinberg, R., Nemoto, T., Dao, T.L.: Vincristine: dosage and response in breast cancer. Cancer Chemother. Rep. 45, 57–61 (1965)
Groupe Européen du Cancer du Sein: Le traitement hormonal du cancer du sein en phase avancée: Comparaison entre le propionate de testosterone et la combinaison propionate de testosterone — delta-1 testololactone. Rev. Fr. Etud. Clin. Biol. 9, 88–90 (1964)
Hanham, I.W.F., Newton, K.A., Westbury, G.: Seventy-five cases of solid tumors treated by a modified quadruple chemotherapy regime. Br. J. Cancer 25, 462–478 (1971)
Harvey, H.A., White, D.S., Lipton, A.: Five drug regimen plus adriamycin in metastatic breast cancer (abstr.). Proc. Am. Soc. Clin. Oncology 16, 255 (1975)
Holland, J., Sharlav, C., Galiani, S. et al.: Vincristine treatment of advanced cancer: a comparative study of 392 cases. Cancer Res. 33, 1258–1264 (1973)
Hoogstraten, B.: Adriamycin (NSC-123 127) in the treatment of advanced breast cancer: studies by the Southwest Oncology Group. Cancer Chemother. Rep. 6/3, 329–334 (1975)
Hoogstraten, B., George, S.L., Samal, B. etal.: Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38, 13–20 (1976)
Horton, J., Dao, T., Cunningham, T., Nemoto, T. et al.: Alternating combination therapy for metastatic breast cancer (abstr.). Proc. Am. Soc. Clin. Oncology. 17, 247 (1976)
Jaffe, N. et al.: Adjuvant methotrexate and citrovorumfactor for treatment of osteogenic sarcoma. N. Engl. J. Med. 291, 944–948 (1974)
James, D.H.: Combination chemotherapy of childhood neuroblastoma. J. Am. Med. Assoc. 194, 123–128 (1965)
Kennedy, B.J., Mielke, P.W. Jr, Fortuny, I.E.: Therapeutic castration versus prophylactic castration in breast cancer. Surg. Gynecol. Obstet. 118, 524–529 (1964)
Leclercq, G., Heuson, J.C., Deboel, M.C., Mattheiem, W.H.: Oestrogen receptors in breast cancer. A changing concept. Br. Med. J. 1975 1, 185–189
Leone, L.S., Rege, V.: Treatment of metastatic, recurrent or inoperable carcinoma of breast with VCR/ Pred/5-FU/Mtx/Cyclo (Reg I) vs. VCR/Pred/5-FU (Reg II) (abstr.). Proc. Am. Assoc. Cancer Res. 14, 125 (1973)
Lloyd, R., Jones, S.E., Salmon, S.E., and Southwest Oncology Group Members: Phase II trial of adriamycin and cyclohphosphamide: a Southwest Oncology Group Pilot Study. Proc. Am. Assoc. Cancer Res. 16, 265 (1975)
Lokich, J.J., Skarin, A.T.: Five drug combination chemotherapy for disseminated adenocarcinoma. Cancer Chemother. Rep. 56, 761–787 (1972)
McGuire, W.L., Carbone, P.P., Vollmer, E.P. (eds.): Estrogen receptors in human breast cancer. New York: Raven Press 1975
McGuire, W.L., Horwitz, K.B, Pearson, O.H., Segaloff, A.: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39, 2934–2974 (1977)
Middleman, E., Luce, J.K., Frei, E.: Clinical trials with adriamycin. Cancer 28, 844–50 (1971)
Muss, H.B., White, D.R., Cooper, M.R., Richards, F.C., Spurr, C.L.: A randomyzed study of two five-drug regimens in advanced breast cancer (abstr.). Proc. Am. Soc. Clin. Oncology 18, 272 (1977)
Nemoto, T., Horton, J., Cunningham, T. etal.: Up date report: comparison of combination chemotherapy (FCP) vs. adriamycin (ADM) vs. adrenalectomy (ADX) in breast cancer (abstr.). Proc. Am. Assoc. Cancer Res. 16, 46 (1975)
Philips, R.F., Higinbotham, N.Z.: The curability of Ewing’s endothelioma of bone in children. J. Pediatr. 70, 391–398 (1967)
Rozencweig, M., Heuson, J.-A.: Breast cancer: prognostic factors and clinical evaluation. In: Cancer therapy: prognostic factors and criteria of response. Staquet, M.J. (ed.), pp. 139–183. New York: Raven Press 1975
Salmon, S., Jones, S.: Chemotherapy of advanced breast cancer with a combination of adriamycin and cyclophosphamide (abstr.). Proc. Am. Assoc. Cancer Res. 15, 90 (1974)
Schabel, F.M.: Concepts for systemic treatment of micrometastases. Cancer 35, 15–24 (1975)
Schabel, M.F.: Rationale for adjuvant chemotherapy. Cancer [Suppl.] 39, 2846–2867 (1977)
Seidman, H.: Cancer of the breast: statistical and epidemiological data. Cancer 24, 1355–1378 (1969)
Smalley, R., Bornstein, R.: C-A-F treatment of metastatic breast carcinoma (abstr.). Proc. Am. Assoc. Cancer Res. 16, 265 (1975)
Smalley, R.V., Murphy, S., Chan, Y.K., Huguely, C.M.: Comparison of two five-drug regimens vs. sequential chemotherapy in metastatic breast carcinoma (abstr.). Cancer Chemother. Rep. 57, 110 (1973)
Stolfi, R.L., Martin, D.S., Fugmann, R.A.: Spontaneous murine mammary adenocarcinoma: model system for evaluation of combined methods of therapy. Cancer Chemother. Rep. 55, 239–249 (1971)
Stoll, B.A. (ed.): Mammary cancer and neuroendocrine therapy. London: Butterworths 1974
Stutz, F.H., Blom, J., Tormey, D.C.: Combination chemotherapy in disseminated carcinoma of the breast. Oncology 29, 139–146 (1974)
Sutow, W.W.: Chemotherapy in childhood cancer (except leukemia). An appraisal. Cancer 18, 1585–1595 (1965)
Sutow, W., Sullivan, P., Fernbach, D.: Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. Proc. Am. Assoc. Cancer Res. 15, 20 (1974)
Tormey, D.C.: Adriamycin (NSC-123 127) in breast cancer: an overview of studies. Cancer Chemotherap. Rep. 6/3, 319–327 (1975a)
Tormey, D.C.: Combined chemotherapy and surgery in breast cancer: a review. Cancer 36, 881–892 (1975b)
Tormey, D.C., Simon, R.M., Lippman, M.E., Bull, J.M., Myers, C.E.: Evaluation of tamoxifen dose in advanced breast cancer. Cancer Treat. Rep. 60, 1451–1459 (1976)
Tormey, D., Carbone, P., Band, P.: Breast cancer survival in single and combination chemotherapy trials since 1968. Proc. Am. Assoc. Cancer Res. 18, 64 (1977)
Welbourn, M.A., Burn, I.J.: Current concepts — treatment of advanced mammary cancer. N. Engl. J. Med. 287, 398–400 (1972)
Whitney, D.J., Smith, D.G., Szilagyi, D.E.: Meaning of five-year cure in cancer of the breast. Arch. Surg. 88, 637–644 (1964)
Young, R.C., Lippman, M.E., DeVita, T.V., Bull, J., Tormey, D.C.: Perspectives in the treatment of breast cancer: 1976. Ann. Intern. Med. 86, 784–798 (1976)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Brunner, K.W. (1982). Hormon- und Chemotherapie. In: Zuppinger, A., Hellriegel, W. (eds) Mammatumoren / Tumours of the Mammary. Handbuch der Medizinischen Radiologie / Encyclopedia of Medical Radiology, vol 19 / 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-95377-4_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-95377-4_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-95378-1
Online ISBN: 978-3-642-95377-4
eBook Packages: Springer Book Archive